Clinuvel Pharmaceuticals Limited
CLVLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $59,372 | $35,648 | $55,921 | $32,802 |
| % Growth | 66.5% | -36.3% | 70.5% | – |
| Cost of Goods Sold | $18,768 | $3,059 | $14,925 | $15,337 |
| Gross Profit | $40,604 | $32,589 | $40,996 | $16,920 |
| % Margin | 68.4% | 91.4% | 73.3% | 51.6% |
| R&D Expenses | $4,564 | $2,840 | $1,596 | $752 |
| G&A Expenses | $26,368 | $486 | $960 | $392 |
| SG&A Expenses | $9,063 | $12,870 | $13,816 | $4,835 |
| Sales & Mktg Exp. | $0 | $12,384 | $12,856 | $4,444 |
| Other Operating Expenses | $0 | $0 | -$6,634 | $0 |
| Operating Expenses | $13,627 | $15,710 | $8,777 | $5,588 |
| Operating Income | $26,977 | $16,879 | $32,219 | $14,473 |
| % Margin | 45.4% | 47.4% | 57.6% | 44.1% |
| Other Income/Exp. Net | $2,643 | $5,053 | $3,654 | $333 |
| Pre-Tax Income | $29,620 | $21,932 | $35,873 | $14,806 |
| Tax Expense | $7,523 | $7,857 | $11,173 | $3,870 |
| Net Income | $22,097 | $14,075 | $24,700 | $10,936 |
| % Margin | 37.2% | 39.5% | 44.2% | 33.3% |
| EPS | 0.44 | 0.28 | 0.49 | 0.22 |
| % Growth | 57.1% | -42.9% | 122.7% | – |
| EPS Diluted | 0.44 | 0.28 | 0.49 | 0.21 |
| Weighted Avg Shares Out | 50,086 | 50,269 | 50,509 | 50,127 |
| Weighted Avg Shares Out Dil | 50,451 | 50,269 | 50,468 | 51,585 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,812 | $2,642 | $3,661 | $3,664 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $574 | $608 | $178 | $965 |
| EBITDA | $30,194 | $16,879 | $34,849 | $21,427 |
| % Margin | 50.9% | 47.4% | 62.3% | 65.3% |